BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 24912512)

  • 1. MGMT testing--the challenges for biomarker-based glioma treatment.
    Wick W; Weller M; van den Bent M; Sanson M; Weiler M; von Deimling A; Plass C; Hegi M; Platten M; Reifenberger G
    Nat Rev Neurol; 2014 Jul; 10(7):372-85. PubMed ID: 24912512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
    Weller M; Stupp R; Reifenberger G; Brandes AA; van den Bent MJ; Wick W; Hegi ME
    Nat Rev Neurol; 2010 Jan; 6(1):39-51. PubMed ID: 19997073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
    Petrova EI; Galstyan SA; Telysheva EN; Ryzhova MV
    Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):52-58. PubMed ID: 38054227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
    Bady P; Delorenzi M; Hegi ME
    J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
    Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
    J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
    Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
    Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
    Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF
    BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
    Oldrini B; Vaquero-Siguero N; Mu Q; Kroon P; Zhang Y; Galán-Ganga M; Bao Z; Wang Z; Liu H; Sa JK; Zhao J; Kim H; Rodriguez-Perales S; Nam DH; Verhaak RGW; Rabadan R; Jiang T; Wang J; Squatrito M
    Nat Commun; 2020 Aug; 11(1):3883. PubMed ID: 32753598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
    Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
    Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
    Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
    PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
    Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.